AGIOS PHARMACEUTICALS INC (AGIO) competitors & alternatives
Health Care · NASDAQ
AGIOS PHARMACEUTICALS INC (AGIO)'s top competitors and alternatives — its most similar public companies — include VERTEX INC CLASS A (VERX), CRISPR THERAPEUTICS AG (CRSP), Ultragenyx (RARE), MIRUM PHARMACEUTICALS INC (MIRM), AMYLYX PHARMACEUTICALS INC (AMLX), XERIS BIOPHARMA HOLDINGS INC (XERS), FULCRUM THERAPEUTICS INC (FULC), BEAM THERAPEUTICS INC (BEAM), ASTRAZENECA PLC (AZN), KRYSTAL BIOTECH INC (KRYS), Sarepta Therapeutics (SRPT) and ATRIUM THERAPEUTICS INC (RNA). These are AGIOS PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top AGIO competitors & alternatives
-
VERTEX INC CLASS AVERXInformation Technology
Vertex automates and governs transaction-based indirect tax compliance across 195 countries for enterprises, embedded into their commerce systems to handle…
$11.05 (as of 2026-07-22) · market cap $1.8B
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
MIRUM PHARMACEUTICALS INCMIRMHealth Care
Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic…
$114.48 (as of 2026-07-22) · market cap $7.0B
-
AMYLYX PHARMACEUTICALS INCAMLXHealth Care
Clinical-stage biotech developing novel therapies for endocrine and neurodegenerative disorders, with a lead GLP-1 receptor antagonist for post-bariatric…
$17.70 (as of 2026-07-22) · market cap $2.0B
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.38 (as of 2026-07-22) · market cap $1.5B
-
FULCRUM THERAPEUTICS INCFULCHealth Care
Fulcrum Therapeutics discovers and develops treatments for genetically-defined rare diseases, with pociredir as a lead clinical-stage program.
$3.70 (as of 2026-07-22) · market cap $248M
-
BEAM THERAPEUTICS INCBEAMHealth Care
Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare…
$26.64 (as of 2026-07-22) · market cap $2.7B
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
KRYSTAL BIOTECH INCKRYSHealth Care
Krystal Biotech is a genetic medicine company leveraging its proprietary HSV-1 vector platform to treat rare diseases, headlined by its FDA-approved topical…
$336.80 (as of 2026-07-22) · market cap $9.9B
-
Sarepta TherapeuticsSRPTHealth Care
A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare…
$15.82 (as of 2026-07-22) · market cap $1.7B
-
ATRIUM THERAPEUTICS INCRNAHealth Care
Atrium is an early-stage biotech pioneering antibody-conjugated RNA therapeutics to treat rare genetic cardiomyopathies by silencing disease-driving genes in…
$12.17 (as of 2026-07-22) · market cap $210M
Not quite? Describe exactly what you want →
Peers are AGIOS PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: AGIOS PHARMACEUTICALS INC (AGIO).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.